(ADCT) ADC Therapeutics - Ratings and Ratios
Antibody, Drug, Conjugate, Therapeutics, Oncology
ADCT EPS (Earnings per Share)
ADCT Revenue
Description: ADCT ADC Therapeutics
ADC Therapeutics SA is a biotechnology company that has developed an antibody drug conjugate (ADC) technology platform, which is being utilized to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. The companys flagship product, ZYNLONTA, has received accelerated approval from regulatory authorities in the US, EU, and China for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
The companys pipeline is diverse, with ZYNLONTA being investigated in various clinical trials, including the LOTIS-5 Phase 3 trial and LOTIS-7 Phase 1b trial, as well as investigator-initiated trials, to expand its use into earlier lines of DLBCL and indolent lymphomas. Additionally, ADC Therapeutics is investigating other ADCs, such as a CD22-targeted compound and ADCT-602, which is in a Phase 1/2 trial for refractory B-cell acute lymphoblastic leukemia.
From a financial perspective, ADC Therapeutics has a market capitalization of $265.94M USD, indicating a relatively small-cap company. The Return on Equity (RoE) of 80.51% suggests that the company is generating significant returns on shareholder equity. To further evaluate the companys performance, other key performance indicators (KPIs) such as Revenue Growth Rate, Research and Development (R&D) Expense as a percentage of Revenue, and Cash Burn Rate could be analyzed.
Some additional KPIs that could be considered when evaluating ADC Therapeutics include the number of patients enrolled in ongoing clinical trials, the pipelines diversity and potential for future approvals, and the companys cash runway. With a strong pipeline and potential for future growth, ADC Therapeutics may be an attractive investment opportunity for those looking to invest in the biotechnology sector.
ADCT Stock Overview
| Market Cap in USD | 396m |
| Sub-Industry | Communications Equipment |
| IPO / Inception | 1979-03-16 |
ADCT Stock Ratings
| Growth Rating | -33.6% |
| Fundamental | 34.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -9.13% |
| Analyst Rating | 4.67 of 5 |
ADCT Dividends
Currently no dividends paidADCT Growth Ratios
| Growth Correlation 3m | 35.8% |
| Growth Correlation 12m | 11.6% |
| Growth Correlation 5y | -81.9% |
| CAGR 5y | -14.38% |
| CAGR/Max DD 3y | -0.16 |
| CAGR/Mean DD 3y | -0.29 |
| Sharpe Ratio 12m | -0.73 |
| Alpha | -2.18 |
| Beta | 0.641 |
| Volatility | 87.41% |
| Current Volume | 310.9k |
| Average Volume 20d | 592.5k |
| Stop Loss | 3.1 (-6.3%) |
| Signal | -0.17 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-169.9m TTM) > 0 and > 6% of Revenue (6% = 4.63m TTM) |
| FCFTA -0.39 (>2.0%) and ΔFCFTA -5.99pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 329.0% (prev 446.1%; Δ -117.0pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.40 (>3.0%) and CFO -127.3m > Net Income -169.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.93 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (113.7m) change vs 12m ago 18.86% (target <= -2.0% for YES) |
| Gross Margin 93.37% (prev 89.53%; Δ 3.84pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 22.28% (prev 17.95%; Δ 4.33pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -2.42 (EBITDA TTM -118.6m / Interest Expense TTM 50.3m) >= 6 (WARN >= 3) |
Altman Z'' -16.47
| (A) 0.79 = (Total Current Assets 318.8m - Total Current Liabilities 64.6m) / Total Assets 321.6m |
| (B) -4.94 = Retained Earnings (Balance) -1.59b / Total Assets 321.6m |
| warn (B) unusual magnitude: -4.94 — check mapping/units |
| (C) -0.35 = EBIT TTM -121.8m / Avg Total Assets 346.7m |
| (D) -3.03 = Book Value of Equity -1.58b / Total Liabilities 520.7m |
| Total Rating: -16.47 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 34.50
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -50.34% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda -0.98 = -2.50 |
| 7. RoE data missing |
| 8. Rev. Trend -58.71% = -2.94 |
| 9. Rev. CAGR -39.87% = -2.50 |
| 10. EPS Trend 37.29% = 0.93 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of ADCT shares?
Over the past week, the price has changed by -5.97%, over one month by +3.76%, over three months by -2.07% and over the past year by +7.47%.
Is ADC Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ADCT is around 2.70 USD . This means that ADCT is currently overvalued and has a potential downside of -18.43%.
Is ADCT a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ADCT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.2 | 147.7% |
| Analysts Target Price | 8.2 | 147.7% |
| ValueRay Target Price | 3 | -9.4% |
Last update: 2025-09-10 04:30
ADCT Fundamental Data Overview
CCE Cash And Equivalents = 264.6m USD (Cash And Short Term Investments, last quarter)
P/S = 5.1264
P/B = 2.5787
Beta = 2.007
Revenue TTM = 77.2m USD
EBIT TTM = -121.8m USD
EBITDA TTM = -118.6m USD
Long Term Debt = 114.5m USD (from longTermDebt, last quarter)
Short Term Debt = 1.79m USD (from shortTermDebt, last quarter)
Debt = 116.3m USD (Calculated: Short Term 1.79m + Long Term 114.5m)
Net Debt = -147.0m USD (from netDebt column, last quarter)
Enterprise Value = 247.7m USD (396.0m + Debt 116.3m - CCE 264.6m)
Interest Coverage Ratio = -2.42 (Ebit TTM -121.8m / Interest Expense TTM 50.3m)
FCF Yield = -50.34% (FCF TTM -124.7m / Enterprise Value 247.7m)
FCF Margin = -161.4% (FCF TTM -124.7m / Revenue TTM 77.2m)
Net Margin = -220.0% (Net Income TTM -169.9m / Revenue TTM 77.2m)
Gross Margin = 93.37% ((Revenue TTM 77.2m - Cost of Revenue TTM 5.12m) / Revenue TTM)
Tobins Q-Ratio = -0.16 (set to none) (Enterprise Value 247.7m / Book Value Of Equity -1.58b)
Interest Expense / Debt = 11.18% (Interest Expense 13.0m / Debt 116.3m)
Taxrate = 21.0% (US default)
NOPAT = -121.8m (EBIT -121.8m, no tax applied on loss)
Current Ratio = 4.93 (Total Current Assets 318.8m / Total Current Liabilities 64.6m)
Debt / EBITDA = -0.98 (Net Debt -147.0m / EBITDA -118.6m)
Debt / FCF = -0.93 (Debt 116.3m / FCF TTM -124.7m)
Total Stockholder Equity = -203.0m (last 4 quarters mean)
RoA = -52.85% (Net Income -169.9m, Total Assets 321.6m )
RoE = unknown (Net Income TTM -169.9m / Total Stockholder Equity -203.0m)
RoCE = unknown (Ebit -121.8m / (Equity -203.0m + L.T.Debt 114.5m))
RoIC = unknown (NOPAT -121.8m, Invested Capital -89.0m, Ebit -121.8m)
WACC = 8.48% (E(396.0m)/V(512.3m) * Re(8.38%)) + (D(116.3m)/V(512.3m) * Rd(11.18%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 3.44%
Discount Rate = 8.38% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -124.7m)
Revenue Correlation: -58.71 | Revenue CAGR: -39.87%
Rev Growth-of-Growth: 85.40
EPS Correlation: 37.29 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 36.27
Additional Sources for ADCT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle